On 15 October 2019, The General Director of the French National Agency for Medical and Health Products (ANSM) issued two Decisions (Decision DG n°2019-365 and 2019-381) in order to pursue the necessary work to set up the medical cannabis pilot programme in France. The decisions create a new French specialised scientific committee (CSST) responsible for the implementation of the medical cannabis pilot programme and define its attributed tasks, and nominate the members thereof.
The two decisions seem to mark the official start of the medical cannabis pilot programme in France which is expected to last two years, and in particular of the first 6 month implementation period.
Read the full article at Lexology
